ReviewInternational journal of obesity (2005)2021
Metabolic dysfunction and immunometabolism in COVID-19 pathophysiology and therapeutics.
Review in International journal of obesity (2005), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 2 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- Deciphering the molecular landscape of hepatopancreatic necrosis disease in Eriocheir sinensis using RNA-Seq meta-analysis.Genes & genomics · 2026Pooled it
- Carbohydrates Metabolic Signatures in Immune Cells: Response to Infection.Frontiers in immunology · 2022Pooled it
- Evolution and Mechanistic Insights of Immunometabolism in Metabolic Diseases and Infections.Scandinavian journal of immunology · 2026Review
- COVID-19 and metabolic health: Lessons from a global pandemic.Metabolism open · 2026Article
- Immunometabolic reprogramming in sepsis: mechanisms, clinical endotypes, and therapeutic opportunities.Frontiers in immunology · 2026Review
- Unraveling the Mystery: COVID-19 and Diabetic Complications - A Journey from Pathophysiology to Treatment.Current diabetes reviews · 2026Review
- Article
- Review
- Measuring Mitochondrial Function of Naïve and Effector CD8 T Cells.Journal of visualized experiments : JoVE · 2025Article
- Understanding the interplay between COVID-19 and diabetes: insights for the post-pandemic era.Frontiers in endocrinology · 2025Review
- COVID-19 Prevalence in Nations with Normal Body Mass Index (BMI): Implications of Artificial Intelligence (AI) in Healthcare.Journal of nutrition & food sciences · 2025Article
- Article
- Upregulation of inflammatory genes and pathways links obesity to severe COVID-19.Biochimica et biophysica acta. Molecular basis of disease · 2024Article
- From Acute Infection to Prolonged Health Consequences: Understanding Health Disparities and Economic Implications in Long COVID Worldwide.International journal of environmental research and public health · 2024Review
- Unveiling the growing significance of metabolism in modulating immune cell function: exploring mechanisms and implications; a review.Annals of medicine and surgery (2012) · 2023Article
- TGF-β uncouples glycolysis and inflammation in macrophages and controls survival during sepsis.Science signaling · 2023Article
- Gut microbiota, malnutrition, and immunity: COVID-19's confounding triad.Cell host & microbe · 2023Article
- Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies.Acta pharmacologica Sinica · 2023Review
- Immunometabolic Signature during Respiratory Viral Infection: A Potential Target for Host-Directed Therapies.Viruses · 2023Review
- Correspondence between Aortic and Arterial Stiffness, and Diastolic Dysfunction in Apparently Healthy Female Patients with Post-Acute COVID-19 Syndrome.Biomedicines · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The COVID-19 pandemic has emerged as a public health crisis and has placed a significant burden on healthcare systems. Patients with underlying metabolic dysfunction, such as type 2 diabetes mellitus and obesity, are at a higher risk for COVID-19 complications, including multi-organ dysfunction, secondary to a deranged immune response, and cellular energy deprivation. These patients are at a baseline state of chronic inflammation associated with increased susceptibility to the severe immune manifestations of COVID-19, which are triggered by the cellular hypoxic environment and cytokine storm. The altered metabolic profile and energy generation of immune cells affect their activation, exacerbating the imbalanced immune response. Key immunometabolic interactions may inform the development of an efficacious treatment for COVID-19. Novel therapeutic approaches with repurposed drugs, such as PPAR agonists, or newly developed molecules such as the antagomirs, which block microRNA function, have shown promising results. Those treatments, alone or in combination, target both immune and metabolic pathways and are ideal for septic COVID-19 patients with an underlying metabolic condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.